

ARTICLES

1. Mulgaonkar S, Jacobs M, Viscuso R, Lyman N: Clinical experience with continuous ambulatory peritoneal dialysis (CAPD). *Kid Int* 1982; 21:174A.
2. Lyman N, Mulgaonkar S, Jacobs M: Hypertriglyceridemia in continuous ambulatory peritoneal dialysis (CAPD). *ASAIO* 11, 1982.
3. Lyman N, Walcer R, Mulgaonkar S, Viscuso R, Jacobs MG: Glucose-K⁺ relationships during continuous ambulatory peritoneal dialysis (CAPD). *Kid Int* 1982; 1:172A.
4. Walcer R, Lyman N, Myers C, Mulgaonkar S: Intraperitoneal insulin (IPI): New alternative for the diabetic CAPD patient. *AANT Jour* 9:43, 1982.
5. Lyman N, Mulgaonkar S, Walcer R, Viscuso R, Jacobs M: Effects of a mineralocorticoid on extrarenal potassium (K⁺) homeostasis in anuric patients. *Kid Int* 1983; 23:155A,.
6. Mulgaonkar S, Lyman N, Viscuso R, Jacobs M: Continuous ambulatory peritoneal dialysis (CAPD). *J Med Soc NJ* 1983; 80(6) :427-430.
7. Lyman N, Michaelson R, Viscuso R, Winn R, Mulgaonkar S, Jacobs M: Mitomycin C induced hemolytic uremic syndrome: Successful treatment with corticosteroids and intense plasma exchange. *Arch Int Med* 1983; 143:1617-1618.
8. Lyman N, Walcer R, Mulgaonkar S, Viscuso R, Jacobs M: Glucose-K⁺ relationships during continuous ambulatory peritoneal dialysis (CAPD): Effects of intraperitoneal insulin. *Kid Int* 1983; 23:155.
9. Lyman N, Iyer R, Mulgaonkar S, Viscuso R, Jacobs M: The effects of dietary protein in glomerular filtration rate (GFR) in normal and in renal transplant recipients. *Kid Int* 1984; 25:345.
10. Mulgaonkar S: Doctor as a detective. *Apple a day* 1985, 1. 11. Mulgaonkar S, Hochman L, Bravo B, Kim DU, Jacobs M, Viscuso R, Lyman N: Atheroembolic renal disease. *Hosp Phys* 27:60-63, 1991.
12. Mulgaonkar S, Jacobs MG, Viscuso R, Lyman N, Bravo B, Clavello A, Filippone D, Dembner A: Laparoscopic internal drainage of lymphocele in renal transplant. *A J Kid Dis* 1992; 19:490-492.
13. DiFillippo W, Mulgaonkar S, Panush R: Bloodletting revisited: Plasmapheresis in the 1990's. *ACP* 1994.
14. Mulgaonkar S, Jacobs M, Viscuso R, Lyman N, Friedman G, Chadha I: Outcome of laparoscopic tenckoff catheter insertion (LTCI) versus surgical tenckoff catheter insertion (STCI): A prospective randomized comparison. *PD Jour* 14:588, 1994.
15. Glazier D, Whang MIS, Geffner S, Lyman N, Friedman G, Viscuso R, Jacobs M, Mulgaonkar S: Evaluation of voiding cystourethrogram prior to renal transplantation. *Transplantation* 1996; 62 (12): 1762-1765.
16. Kaplan B, Friedman G, Jacobs M, Viscuso R, Lyman N, DeFranco P, Bonomini B, and Mulgaonkar S: Potential interaction of troglitazone and cyclosporine. *Transplantation* 1998; 65:1399-1400.
17. Glazier DB, Jacobs MG, Lyman NW, Whang MIS, Manor E, Mulgaonkar S: Urinary tract infection associated with ureteral stents in renal transplantation. *Canadian Journal of Urology* 1998; 5:462-466.
18. Kaplan B, Meier-Kriesche HU, Jacobs MG, Friedman G, Bonomini L, DeFranco P, Gelfand E, Mulgaonkar S: Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain.

Am J Kidney Disease 34(1): 65-8, 1999.

19. Kaplan B, Friedman G, Mulgaonkar S, Kureka M, and Shaw L: The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharm 1999; 39:715-720.
20. Meier-Kriesche HU, Friedman G, Jacobs M, Mulgaonkar S, Vaghela M, and Kaplan B: Infectious complications in geriatric renal transplant patients: Comparison of two immunosuppressive protocols. Transplantation 1999; 68:1496-1502.
21. Meier-Kriesche HU, Palekar S, Friedman G, Mulgaonkar S, Goldblat, M, and Kaplan B: Efficacy of Daclizumab in an African-American and Hispanic renal transplant population. Transplant Int 2000; 13(2): 142-145.
22. Kaplan b, Vaghela M, Meier-Kriesche HU, Friedman G, Mulgaonkar S, and Jacobs M: Withdrawal of Mycophenolate mofetil in stable renal transplant recipients. Transplantation 2000; 69(8): 1726-1728.
23. Kaplan B, Friedman G, Mulgaonkar S, Kureka M, and Shaw L: Effect of renal insufficiency on mycophenolic acid protein binding, J Clin Pharm 1999; 39(7): 715-720.
24. Herwig-Ulf Meier-Kriesche, Sadanand Palekar, Gary Friedman, Shamkant Mulgaonkar, Melvin Goldblat, Bruce Kaplan: Efficacy of Daclizumab in an African-American and Hispanic renal transplant population: Transplant Int 2000; 13:142-145.
25. Whang M, Katz L, Ongcapin E, Geffner S, Friedman G, Mulgaonkar S, and Kaplan B: Nephrogenic adenomas occurring in a patient with simultaneous kidney-pancreas transplant. Urology 2000; 55(6): 949.
26. Kaplan B, Cheema A, Friedman G, Shah N, Mulgaonkar S, Defranco P: Unmasking of primary hyperaldosteronism by renal transplantation: Transplantation 2000; 69: 7, 1503-1505.
27. Friedman GS, Wik D, Silva L, Meier-Kriesche HU, Kaplan B, Mulgaonkar S, Jacobs M: Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistance. Transplantation 2000; 69 (10): 2099-2102.
28. Meier-Kriesche HU, Kaza H, Palekar SS, Friedman GS, Mulgaonkar S, Ojo AO, Kaplan B: The effect of Daclizumab in a high-risk renal transplant population. Clin Transplant; 2000, 14(5): 509-513.
29. Friedman GS, Bonomini L, Kaplan B, Meier-Kriesche HU, Mulgaonkar S: Hypercoagulable states in renal transplant candidates: Impact of anticoagulation upon incidence of renal allograft thrombosis. Transplantation 2001; 72(6):1073-78.
30. Matthew Whang, Stuart Geffner, Zareh Khachikian, Ashok Kumar, Luigi Bonomini, Shamkant Mulgaonkar: Renal transplantation and prostate cancer: Guidelines for screening and treatment. Transplant proceedings 2002; 34, 3196-3199.
31. Barry D.Kahan, Janet L.Karlix, Ronald M.Ferguson, Alan B. Leichtman, Shamkant Mulgaonkar, Thomas A.Gonwa, Andrej Skerjanec, Robert L.Schmouder, and Lawrence Chodoff: Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY 720 in stable renal transplant patients: A multicenter, randomized, placebo-controlled, phase I study. Transplantation 2003; 76, 1079-1084.
32. Andrea Tietjen, Jenoveva Orsini, Shamkant Mulgaonkar, Debra Morgan: Clinical integration of billing for a pediatric nephrology and transplant program. Progress in Transplantation 2003; 13, No.3.
33. Shamkant Mulgaonkar: ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. American Journal of Transplantation 2003; 4:237-243.

34. Helio Tedesco-Silva, Georges Mourad, Barry D Kahan, Joseph Grinyo Boira, Willem Weimar, Shamkant Mulgaonkar, Bjorn Nashan, Soren Madsen, B. Carpentier, Pascale Pellet. Yves Vanrenterghem: FTY720- A novel immunomodulator- Efficacy and safety results from the first phase 2 a study in DE NOVO renal transplantation. Transplantation 2004; 77:12, 1826-1833.
35. A.Scott Mathis, Nita K.Shah, Shamkant Mulgaonkar: Stress dose steroids in renal transplant patients undergoing lymphocele surgery. Transplant Proceedings 2004; 36, 3042-3045.
36. Marc Lorber, Shamkant Mulgaonkar, Khalid Butt, Elmahdi, Robert Mendez, P.R. Rajagopalan, Barry Kahan, Hans Sollinger, Angela Falcone, Yulan Li, Natalie Cretin-Buehler, Helio Tadesco and B251 Study Group: Everolimus versus Mycophenolate Mofetil in prevention of rejection in de novo renal transplant recipients: a three- year randomized, multicenter, phase 3 study. Transplantation 2005; 80:2, 244-252.
37. Shamkant Mulgaonkar, Helio Tadesco, Federico Oppenheimer, Rowan Walker, Ulrich Kunzendorf, Graeme Russ, Andreas Knoflach, Yogesh Patel, Ronald Fergusson, for the FTY A 121 study group: FTY 720/cyclosporine regimens in de novo renal transplantation: A 1-year dose finding study. AJ Transplantation 2006; 6:1-10; 1848-1857.
38. Laurence K Chan, Shamkant Mulgaonkar, Rowan Walker, Wolfgang Arns, Patrice Ambuhl, Ruben Schiavelli: Patient-reported gastrointestinal symptom burden and health-related quality of life in renal transplant recipients following conversion from Mycophenolate Mofetil to enteric-coated Mycophenolate sodium. Transplantation 2006; 81:9, 1290-1297.
39. Mark Pescovitz, Flavio Vincenti, Marquis Hart, Larry Melton, John Whelchel, Shamkant Mulgaonkar, Diane McKay, Mimi Leung, Elizabeth Calleja, Rene Bouw: Pharmacokinetics, safety, and efficacy of Mycophenolate Mofetil in combination with Sirolimus or ciclosporine in renal transplant patients, Br J Clin Pharmacol. 2007; 64 (6):758-771.
40. Federic Oppenheimer, Shamkant Mulgaonkar, Ronald Fergusson, Josef Grinyo, Federico Juarez, Merek Ostrowski, Marian Klinger, Rowan Walker, Armando Torres, Hartmut Meyer and Alan Jardine : Impact of Long-term therapy with FTY720 or Mycophenolate Mofetil on cardiac conduction and rhythm in stable adult renal transplant patients. Transplantation; 2007; 15;83(5): 645-648.
41. Francis L. Weng, MD, MSCE, Anup M. Patel, MD, Rimda Wanchoo, MD, Yasmin Brahmabhatt, MD, Kezia Ribeiro, MD, Marc E. Uknis, MD, Shamkant Mulgaonkar, MD, A. Scott Mathis, Pharm D: Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Transplantation 2007; 83, (5) 645-648.
42. Helio Tedesco-Silva, Mark D. Pescovitz, Diane Cibrik, Michael A. Rees , Shamkant Mulgaonkar, Barry D. Kahan , Kristene K. Gugliuzza, P.R. Rajagopalan, Ronaldo de M. Esmeraldo, Hélène Lord, Maurizio Salvadori, and Jennifer M. Slade, for the FTY720 0125 study group: Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 2006; 82:12, 1689-1697.
43. Mark Pescovitz MD, Ashok Jain MD, Richard Robson MD, Shamkant Mulgaonkar MD, Richard B. Freeman MD, M.Rene Bouw, Ph.D: Establishing pharmacokinetic bioequivalence of Valgancyclovir oral solution versus the tablet formulation. Transplant Proc. 2007; 39(10):3111-6.
44. Anup Patel, MD, Carol Pancoska, PhD, Shamkant Mulgaonkar,MD, Francis Weng, MD,MSCE :Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007; 7(10):2371-7.
45. S Busque, J Leventhal, D Brennan, S Steinberg, G Klintmalm, T Shah, S Mulgaonkar, J Bromberg, F Vincenti, S Hariharan, T Batiuk, D Thomas, D Slakey, R Peddi, A Wiseman, R Fisher, N Lawendy, C Wang and G Chan Efficacy and safety of calcineurin-inhibitor free regimens based on the novel JAK3 inhibitor CP-690,550: results of a phase 2a study in de novo renal allograft recipients. Am J Transplant. 2009; 9(8):1936-45.

46. Robert Gaston, Bruce Kaplan, Tarique Shah, Diane Cibrik, Michael Angelis, Shamkant Mulgaonkar, Herwig Meier-Kriesche, Dharmesh Patel, Roy Bloom: Fixed and Concentration-Controlled Dosing of Mycophenolate Mofetil with Standard or Reduced Dose Calcineurin Inhibition: Final One-Year Results of the Optcept Trial. *Am J Transplant* 2009; Jul;9(7):1607-19.
47. E. Steve Woodle, V. Ram Peddi, Steven Tomlanovich, Shamkant Mulgaonkar, Paul C. Kuo : A Prospective, Randomized, Multicenter Study Comparing Early Corticosteroid Withdrawal Under Thymoglobulin® Induction with Maintenance Corticosteroid Therapy in Living-Donor Kidney Transplantation. *Clinical Transplantation* 2010; 24(1):73-83.
48. Michael Hanaway, E. Steve Woodle, Shamkant Mulgaonkar, Ram Peddi, Dixon Kaufman, Roy First, John Holman for INTAC Study Group: A randomized trial comparing Alemtuzumab to Thymoglobulin Induction in High risk and Basiliximab induction in Low risk kidney transplant recipients under early corticosteroid withdrawal : 3 year Results. *NEJM* 2011; 364:1909-1919.
49. Gaber A.O. , Mulgaonkar S. , Kahan B., Woodle E.S. , Alloway R., Bajjoka I., Jensik S., Klintmalm G., Patton P., Wiseman A., Busuttil R.W. , Gaber L.W., Katz E., Irish W., Squiers E.C., and Hemmerich S. YSPSL (rPSGL-Ig) for Improvement of Early Renal Allograft Function: A Double-Blind, Placebo-Controlled, Multi-Center Phase IIa Study. *Clin Transplant.* 2011 Jul; 25(4):523- 533.
50. M. R. Weir, S. Mulgaonkar, L. Chan, H. Shidban,T. Waid, D. Preston, T. C. Pearson: Mycophenolate Mofetil-based Immunosuppression with Sirolimus in Renal Transplantation: 2-Year Results of the Spare-the-Nephron Trial. *Kidney International* (April (2) 2011); 79, 897-907.
51. S Friman, W Arns, B Banas, K Budde, D Cibrik5, L Chan, J Klempnauer, S Mulgaonkar, B Nashan, M Nicholson1, F Vincenti, J Wahlberg, K-M Wissing, K Abrams, S Witte, ES Woodle: Sotrastaurin, a novel small molecule inhibiting protein kinase C: randomized Phase II study in renal-transplant recipients. *Am J Transplant* 2011; 11: 1444-1455.
52. Francis L. Weng, Peter P. Reese, Shamkant Mulgaonkar, Anup M. Patel: Barriers to living donor kidney transplantation among black, female and older recipients. *CJASN* 2010; 5: 2338-2347.
53. S. Busque, M. Cantaovich, S. Mulgaonkar, R.Gaston, AO Gaber, P.R.Mayo, S. Ling, R Huizinga, H Meier-Kriesche: The Promise Study: A phase 2b Multicenter Study of Voclosporine (ISA 247) versus Tacrolimus in de novo kidney transplantation. *Am J Transplant* 2011; 11: 2675-2684.
54. Francis Weng, Peter Reese, Amy Waterman, Angelo Soto, Kitaw Demissie, Shamkant Mulgaonkar: Health care utilization and post-donation comorbidities of live kidney donors more than 3 years post-nephrectomy. *Clin Transplant* 2012; 26: E300–E306.
55. M. Whang, M. Yballe, S. Geffner, H.S. Fletcher, S. Palekar, S. Mulgaonkar Urologic Complications in More Than 2500 Kidney Transplantations performed at the Saint Barnabas Healthcare System Transplantation Proceedings, June 2011 Volume 43, issue 5, 1619 -1622.
56. Matthew Cooper M.D., Diane M. Cibrik M.D. M.S., Shamkant Mulgaonkar MD FASN, Joseph Melancon M.D., Clifton E Kew, II M.D.A review of potential benefits of Everolimus for improved long term survival following kidney transplantation. Submitted to *CJSAN*.
57. Björn Nashan; Robert Gaston; Vincent Emery; Marcus Saemann; Nicolas J Mueller; Lionel Couzi; Jacques Dantal; Fuad Shihab; Shamkant Mulgaonkar; Yu Seun Kim; Daniel C. Brennan. Cytomegalovirus infection findings with mTOR inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. *Transplantation*; (93): 11, June 15, 2012, 760-769.

58. Rahul V. Pawar, Shamkant Mulgaonkar: So It's a Mass- Let's take it a step further. On the case: Radiology today. May 2011.
59. Matthew Cooper MD, Sandip Kapur MD, Robert Stratta MD, Anthony M. D'Alessandro MD, Shamkant Mulgaonkar MD, Mary E. Russell PhD, Susan B. Rodriguez PhD, Gordon Ringold PhD, Anthony Allison MD, PhD, Stuart J. Knechtle MD. A Randomized, Controlled Clinical Trial of Diannexin, a Novel Blocker of Ischemia-Reperfusion Injury, Improves Graft Function in Recipients of Marginal Donor Renal Transplants. Submitted to Ann of Surgery 2011.
60. Francis Weng, Navdeep Dhillon, Yong Lin, Shamkant Mulgaonkar, Anup Patel. Racial differences in outcomes of evaluation of the potential live kidney donors: A retrospective cohort study. Am J of Nephrology 2012; 35: 409- 415.
61. M. L. Melcher, D. B. Leiser, A. Gritsch, J. Milner, S. Kapur, S. Busque, J. P. Roberts, S. Katznelson, W. Bry, H. Yang, A. Lud, S. Mulgaonkar, G. M. Danovitch, G. Hil and J. L. Veale: Chain Transplantation: Initial Experience of a Large Multicenter Program. Am J Transplant 2012;12:2429-2436.
62. S. Bunnapradist*, K. Ciechanowski, P. West-Thielke, S. Mulgaonkar, L. Rostaing, B. Vasudev, K. Budde : Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus: The Phase III Randomized MELT Trial. Am J Transplant 2013;13: 760-769.
63. Melacon K, Mulgaonkar, S, Delcoro C, Wiland A, McCague K, Shihab FS: Outcomes in Ethnic Minority Renal Transplant recipients receiving Everolimus versus mycophenolate. Comparative risk assessment. Results from a pooled analysis. Transplantation 96 (12): 1073-1081
64. Stuart M. Fletcher, Shamkant Mulgaonkar, Larry B Melton, Thomas H Waid, Avinash Agarwal, Stephen D Miller, Frank Fokta, Meghann T Getts, Terra J Frederick, James J Herrmann, John P Puisis, Leslie O'Toole, Randall Sung, Fuad Shihab, Alexander C Wiseman, and Daniel R Getts, First in Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection. Am J Transplant 2014
65. Mulgaonkar, S, Kaufman DB, Conversion from calcineurin inhibitor -based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients. Clinical Transplantation 2014: 28: 1209-1224